Skip to main content
Premium Trial:

Request an Annual Quote

Mount Sinai, Regeneron Launch Sequencing Project to Augment Genetics-Based Precision Medicine

NEW YORK – Mount Sinai Health System and the Icahn School of Medicine at Mount Sinai said on Friday that they have launched a new large-scale human genome sequencing research project with New York-based biotechnology company Regeneron.

The program, named Mount Sinai Million Health Discoveries Program, aims to enroll 1 million Mount Sinai patients over a five-year period, offering researchers the dataset to assess the potential of genetics-based precision medicine as well as to generate new insights for potential new therapy discoveries and development.

The collaboration will synergize Regeneron's gene sequencing capabilities and scientific research expertise through its Regeneron Genetics Center with Mount Sinai's large, diverse patient population and advanced electronic health records systems.

According to Mount Sinai, the program will be administered by its Charles Bronfman Institute for Personalized Medicine and will be part of other initiatives within the Institute, including multimodal data science, deep phenotyping of patients with informative genetic variation, and last-mile experimental interventions to rigorously test new treatments before they are incorporated into clinical care.

Meanwhile, the Regeneron Genetics Center will perform exome sequencing and whole-genome genotyping-by-sequencing analysis on all DNA samples, as well as whole-genome sequencing on a large subset of samples.

"Our ultimate hope is that we can use genetics to help all patients," Alexander Charney, associate professor of psychiatry and genetics and genomic sciences at Icahn Mount Sinai and project leader, said in a statement.

Vibrent Health, a digital health solutions company that provides the technology platform for the National Institutes of Health's million-person All of Us Research Program, will provide the project with a privacy-preserving platform for e-consenting, data collection, and engagement for clinical research.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.